Multiple studies had focused on the association between interleukin-1 (IL-1) rs1143634 polymorphism and aggressive periodontitis (AgP) susceptibility, but the results remained inconclusive. Therefore, this meta-analysis was conducted to explore its role in the development of AgP. PubMed and Embase databases were searched up to April 15, 2014. After study selection and data extraction form eligible studies, meta-analysis was performed. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the association. All the analysis was performed using Comprehensive Meta-Analysis software. Finally a total of 25 case-control studies were included. The pooled results showed non-association between AgP susceptibility and IL-1 rs1143634 polymorphism [for T vs. C: OR = 0.99, 95% CI = 0.79-1.23; for TT vs. CC: OR = 1.14, 95% CI = 0.78-1.66; for CT vs. CC: OR = 0.97, 95% CI = 0.70-1.36; for (CT + TT) vs. CC: OR = 1.02, 95% CI = 0.76-1.37; for TT vs. (CT + CC): OR = 1.22, 95% CI = 0.85-1.75]. Subgroup analyses remain did not find any association. No publication bias was detected. Hence, our meta-analysis showed that IL-1β rs1143634 polymorphism is not linked to AgP susceptibility, regardless of ethnicity.
To explore the correlation between propagated sensation along meridian (PSM) and TCM constitution at different age stages.According to age, 840 participants were divided into a youth group (326 cases), a middle aged group (243 cases) and an elderly group (271 cases). The TCM constitution of all the participants was evaluated, and the PSM test was performed. The distribution of TCM constitution, the occurring rate and transmission of PSM in each group were observed and compared; the correlation between PSM and the TCM constitution was preliminary investigated by Logistic regression analysis.The distribution of nine types of TCM constitution in three groups:the proportion of normal constitution and partial constitution were significantly different (all P<0.05); the occurring rate and transmission of PSM in three groups were not significantly different (all P>0.05); the proportion of occurring rate for nine types of TCM constitutions in the whole population, from high to low, presented special intrinsic quality, neutral quality, yin-deficiency quality, qi-deficiency quality, yang-deficiency quality, damp-heat quality, phlegm-dampness quality, qi-stagnation quality and blood-stasis quality; besides, the proportion of occurring rate for different TCM constitutions in the youth group, middle aged group and elderly group was similar to that of whole population. The Logistic regression analysis results indicated the neutral quality (P=0.025) and special intrinsic quality (P=0.018) were positively while blood-stasis quality (P=0.043) was negatively related with PSM in all subjects; the qi-deficiency quality (P=0.025), phlegm-dampness quality (P=0.019), blood-stasis quality (P=0.012) and qi-stagnation quality (P=0.035) were negatively related with PSM in youth group; the neutral quality (P=0.001) was positively related with PSM inthe middle aged group; the neutral quality (P=0.006) and yin deficiency quality (P=0.004) were positively related with PSM in the elderly group.The occurrence of PSM in different age stages is related with TCM constitution, which could be increased in clinical treatment to improve acupuncture efficacy.
Lichen planus is a chronic inflammatory skin disease. Due to its unclear etiology, the treatment is slow and complicated. Rubia cordifolia is a drug with a long history, with the effects of cooling blood and removing blood stasis, promoting blood circulation, and dredging meridians. Modern research suggests that the components of Rubia cordifolia have the effects of immune regulation, anti-inflammation, liver protection, and antioxidation. It may be a potential drug for the treatment of lichen planus. However, the specific mechanism of Rubia cordifolia in the treatment of this disease is still under study. This article reviews the mechanism of Rubia cordifolia in the treatment of lichen planus, in order to provide references for the clinical application of the drug.